Faculty Profiles - MORISE Masahiro

Papers - MORISE Masahiro

Division display 1 - 20 of about 93 ／ All the affair displays >>

Efficacy and safety of second-line therapy of docetaxel plus ramucirumab after first-line platinum-based chemotherapy plus immune checkpoint inhibitors in non-small cell lung cancer (SCORPION): a multicenter, open-label, single-arm, phase 2 trial Invited Reviewed International journal

Matsuzawa, R; Morise, M; Ito, K; Hataji, O; Takahashi, K; Koyama, J; Kuwatsuka, Y; Imaizumi, K; Goto, Y; Itani, H; Yamaguchi, T; Zenke, Y; Oki, M; Ishii, M

ECLINICALMEDICINE Vol. 66 page： 102303 2023.12

Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC Reviewed International coauthorship International journal

Herbst Roy S., Giaccone Giuseppe, de Marinis Filippo, Reinmuth Niels, Vergnenegre Alain, Barrios Carlos H., Morise Masahiro, Felip Enriqueta, Andric Zoran, Geater Sarayut, Ozguroglu Mustafa, Zou Wei, Sandler Alan, Enquist Ida, Komatsubara Kimberly, Deng Yu, Kuriki Hiroshi, Wen Xiaohui, McCleland Mark, Mocci Simonetta, Jassem Jacek, Spigel David R.

NEW ENGLAND JOURNAL OF MEDICINE Vol. 383 ( 14 ) page： 1328 - 1339 2020.10

Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trial. Reviewed International coauthorship International journal

Wu YL, Guarneri V, Voon PJ, Lim BK, Yang JJ, Wislez M, Huang C, Liam CK, Mazieres J, Tho LM, Hayashi H, Nhung NV, Chia PL, de Marinis F, Raskin J, Zhou Q, Finocchiaro G, Le AT, Wang J, Dooms C, Kato T, Nadal E, Hin HS, Smit EF, Wermke M, Tan D, Morise M, O'Brate A, Adrian S, Pfeiffer BM, Stroh C, Juraeva D, Strotmann R, Goteti K, Berghoff K, Ellers-Lenz B, Karachaliou N, Le X, Kim TM, INSIGHT 2 investigators

The Lancet Oncology Vol. 25 ( 8 ) page： 989 - 1002 2024.8

Randomized, Double-Blind, Phase III Study of Fosnetupitant Versus Fosaprepitant for Prevention of Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: CONSOLE Reviewed International journal

Hata, A; Okamoto, I; Inui, N; Okada, M; Morise, M; Akiyoshi, K; Takeda, M; Watanabe, Y; Sugawara, S; Shinagawa, N; Kubota, K; Saeki, T; Tamura, T

JOURNAL OF CLINICAL ONCOLOGY Vol. 40 ( 2 ) page： 180 - + 2022.1

Clinical Significance of a Prospective Large Genomic Screening for SCLC: The Genetic Classification and a Biomarker-Driven Phase 2 Trial of Gedatolisib. Reviewed International journal

Umemura S, Udagawa H, Ikeda T, Murakami H, Daga H, Toyozawa R, Kozuki T, Sakakibara-Konishi J, Ohe Y, Morise M, Kato T, Shingyoji M, Hara S, Furuya N, Teranishi S, Takata S, Miyamoto S, Nakachi I, Wakabayashi M, Nomura S, Sato A, Ishii G, Tsuchihara K, Sugiyama E, Kirita K, Sakai T, Shibata Y, Izumi H, Nosaki K, Zenke Y, Matsumoto S, Yoh K, Niho S, Goto K

JOURNAL OF THORACIC ONCOLOGY Vol. 20 ( 2 ) page： 177 - 193 2025.2

Updated Overall Survival Analysis From IMpower110: Atezolizumab Versus Platinum-Based Chemotherapy in Treatment-Naive Programmed Death-Ligand 1-Selected NSCLC Reviewed International coauthorship International journal

Jassem, J; de Marinis, F; Giaccone, G; Vergnenegre, A; Barrios, CH; Morise, M; Felip, E; Oprean, C; Kim, YC; Andric, Z; Mocci, S; Enquist, I; Komatsubara, K; McCleland, M; Kuriki, H; Villalobos, M; Phan, S; Spigel, DR; Herbst, RS

JOURNAL OF THORACIC ONCOLOGY Vol. 16 ( 11 ) page： 1872 - 1882 2021.11

Therapeutic Priority of the PI3K/AKT/mTOR Pathway in Small Cell Lung Cancers as Revealed by a Comprehensive Genomic Analysis Reviewed International journal

JOURNAL OF THORACIC ONCOLOGY Vol. 9 ( 9 ) page： 1324 - 1331 2014.9

Trastuzumab emtansine for patients with non-small cell lung cancer positive for human epidermal growth factor receptor 2 exon-20 insertion mutations Reviewed International journal

Iwama, E; Zenke, Y; Sugawara, S; Daga, H; Morise, M; Yanagitani, N; Sakamoto, T; Murakami, H; Kishimoto, J; Matsumoto, S; Nakanishi, Y; Goto, K; Okamoto, I

EUROPEAN JOURNAL OF CANCER Vol. 162 page： 99 - 106 2022.2

Efficacy and safety of tepotinib in Asian patients with advanced NSCLC with MET exon 14 skipping enrolled in VISION. Reviewed International coauthorship International journal

Kato T, Yang JC, Ahn MJ, Sakai H, Morise M, Chen YM, Han JY, Yang JJ, Zhao J, Hsia TC, Berghoff K, Bruns R, Vioix H, Lang S, Johne A, Le X, Paik PK

Vol. 130 ( 10 ) page： 1679 - 1686 2024.6

A phase I/II study of osimertinib in EGFR exon 20 insertion mutation-positive non-small cell lung cancer Reviewed International journal

Yasuda, H; Ichihara, E; Sakakibara-Konishi, J; Zenke, Y; Takeuchi, S; Morise, M; Hotta, K; Sato, M; Matsumoto, S; Tanimoto, A; Matsuzawa, R; Kiura, K; Takashima, Y; Yano, S; Koyama, J; Fukushima, T; Hamamoto, J; Terai, H; Ikemura, S; Takemura, R; Goto, K; Soejima, K

Vol. 162 page： 140 - 146 2021.12

Nationwide prospective registry database of patients with newly diagnosed untreated pleural mesothelioma in Japan Reviewed International journal

Hasegawa, S; Shintani, Y; Takuwa, T; Aoe, K; Kato, K; Fujimoto, N; Hida, Y; Morise, M; Moriya, Y; Morohoshi, T; Suzuki, H; Chida, M; Endo, S; Kadokura, M; Okumura, M; Hattori, S; Date, H; Yoshino, I

CANCER SCIENCE Vol. 115 ( 2 ) page： 507 - 528 2024.2

Long-term experience with tepotinib in Japanese patients with MET exon 14 skipping NSCLC from the Phase II VISION study Reviewed International coauthorship International journal

Morise, M; Kato, T; Matsumoto, S; Inoue, T; Sakamoto, T; Tokito, T; Atagi, S; Kozuki, T; Takeoka, H; Chikamori, K; Shinagawa, N; Tanaka, H; Horii, E; Adrian, S; Bruns, R; Johne, A; Paik, PK; Sakai, H

CANCER SCIENCE Vol. 115 ( 4 ) page： 1296 - 1305 2024.4

Artificial intelligence-based personalized survival prediction using clinical and radiomics features in patients with advanced non-small cell lung cancer. Reviewed International journal

Koyama J, Morise M, Furukawa T, Oyama S, Matsuzawa R, Tanaka I, Wakahara K, Yokota H, Kimura T, Shiratori Y, Kondoh Y, Hashimoto N, Ishii M

BMC cancer Vol. 24 ( 1 ) page： 1417 2024.11

Non-invasive early prediction of immune checkpoint inhibitor efficacy in non-small-cell lung cancer patients using on-treatment serum CRP and NLR Reviewed International journal

Matsuzawa, R; Morise, M; Kinoshita, F; Tanaka, I; Koyama, J; Kimura, T; Kondoh, Y; Tanaka, T; Shima, K; Hase, T; Wakahara, K; Ishii, M; Hashimoto, N

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY Vol. 149 ( 7 ) page： 3885 - 3893 2023.7

A multicenter cohort study of osimertinib compared with afatinib as first-line treatment for EGFR-mutated non-small-cell lung cancer from practical dataset: CJLSG1903 Reviewed International journal

Ito, K; Morise, M; Wakuda, K; Hataji, O; Shimokawaji, T; Takahashi, K; Furuya, N; Takeyama, Y; Goto, Y; Abe, T; Kato, T; Ozone, S; Ikeda, S; Kogure, Y; Yokoyama, T; Kimura, M; Yoshioka, H; Murotani, K; Kondo, M; Saka, H

ESMO OPEN Vol. 6 ( 3 ) page： 100115 2021.6

Clinicopathological significance of cancer stem-like cell markers in high-grade neuroendocrine carcinoma of the lung Reviewed International journal

Morise M, Hishida T, Takahashi A, Yoshida J, Ohe Y, Nagai K, Ishii G

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY Vol. 141 ( 12 ) page： 2121 - 2130 2015.12

Nongenomic Effects of Fluticasone Propionate and Budesonide on Human Airway Anion Secretion Reviewed International journal

Mizutani, T; Morise, M; Ito, Y; Hibino, Y; Matsuno, T; Ito, S; Hashimoto, N; Sato, M; Kondo, M; Imaizumi, K; Hasegawa, Y

AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY Vol. 47 ( 5 ) page： 645 - 651 2012.11

Capsaicinoids Regulate Airway Anion Transporters through Rho Kinase- and Cyclic AMP-Dependent Mechanisms Reviewed International journal

Hibino, Y; Morise, M; Ito, Y; Mizutani, T; Matsuno, T; Ito, S; Hashimoto, N; Sato, M; Kondo, M; Imaizumi, K; Hasegawa, Y

AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY Vol. 45 ( 4 ) page： 684 - 691 2011.10

Heterologous regulation of anion transporters by menthol in human airway epithelial cells Reviewed International journal

Morise, M; Ito, Y; Matsuno, T; Hibino, Y; Mizutani, T; Ito, S; Hashimoto, N; Kondo, M; Imaizumi, K; Hasegawa, Y

EUROPEAN JOURNAL OF PHARMACOLOGY Vol. 635 ( 1-3 ) page： 204 - 211 2010.6

Phase II study of erlotinib for previously treated patients with EGFR wild-type non-small-cell lung cancer, following EGFR mutation status reevaluation with the Scorpion Amplified Refractory Mutation System. Reviewed International journal

Morise M, Taniguchi H, Saka H, Shindoh J, Suzuki R, Kojima E, Hase T, Ando M, Kondo M, Saito H, Hasegawa Y

MOLECULAR AND CLINICAL ONCOLOGY Vol. 2 ( 6 ) page： 991 - 996 2014.11

　 PREV - NEXT 　

<MORISE Masahiro>

Papers - MORISE Masahiro